2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, jco2402219. PMID: 40048689, DOI: 10.1200/jco-24-02219.Peer-Reviewed Original ResearchMelanoma brain metastasesOverall survivalBrain metastasesAnti-vascular endothelial growth factor therapyMedian intracranial progression-free survivalFour-year OS ratesIntracranial progression-free survivalResponse rateCirculating angiopoietin-2Median overall survivalTrial of pembrolizumabYears of pembrolizumabDose of bevacizumabProgression-free survivalPhase II trialGrowth factor therapyAdverse event ratesAssociated with responseOS ratesPD-1Radiation necrosisLocal therapyOn-therapyMetastatic tumorsFactor therapyEVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES. Urologic Oncology Seminars And Original Investigations 2025, 43: 43. DOI: 10.1016/j.urolonc.2024.12.109.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaNational Cancer DatabaseMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalImpact of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsPrimary treatment typeCox proportional hazards analysisSite of metastasisEvaluate clinical outcomesProportional hazards analysisBorderline statistical significancePT0 rateOS benefitHistological subtypesCancer DatabaseClinical stageClinical outcomesTreatment patternsCurrent therapiesInstitutional experiencePrimary outcome
2024
Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalTreatment patternsReceipt of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsCox proportional hazards analysisEvaluate treatment patternsSite of metastasisProportional hazards analysisPT0 rateOS benefitHistological subtypesClinical stageCurrent therapiesInstitutional experiencePrimary outcomeNCDBTreatment trendsEffective treatmentPatientsCarcinoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply